Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

L-TAT control peptide (FITC conjugate)

Control peptide for L-JNKI
 
ALX-168-009F-R050 50 µl FITC 86.00 USD
Do you need bulk/larger quantities?
 
Control peptide for L-JNKI. For more details see L-JNKI1 (Prod.No. BML-EI354).

Product Specification

Alternative Name:JNK Inhibitor 1 (L-stereoisomer) control peptide (FITC conjugate)
 
Sequence:FITC-β-A-RKKRRQRRRA-amide
 
Formula:C80H128N34O17S
 
MW:1870.2
 
Concentration:1mM
 
Formulation:Liquid. In sterile PBS.
 
Purity:≥90% (HPLC)
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Handling:Keep on ice at all times. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
 

Product Literature References

Hyperosmolarity and CD95L trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation: R. Reinehr, et al.; FASEB J. 17, 731 (2003), Abstract; Full Text
Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death: C. Bonny, et al.; Diabetes 50, 77 (2001), Abstract; Full Text

Related Products

L-JNKi1 

Jnk inhibitor
≥95% (HPLC) | Print as PDF
 
BML-EI354-0001 1 mg 328.00 USD
Do you need bulk/larger quantities?
 

NBD peptide / NF-κB blocker (cell permeable) 

≥95% (HPLC) | Print as PDF
 
ALX-163-011-1 1 Vial 274.00 USD
Do you need bulk/larger quantities?
 

Bax (human) (58-75), (cell permeable) 

≥95% (HPLC) | Print as PDF
 
ALX-152-028-1 1 Vial 180.00 USD
Do you need bulk/larger quantities?
 

Related Literature

Brochures
Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,